Investor Relations

Stock price graph

Retrophin, Inc. (NASDAQ: RTRX) is a publicly-traded, San Diego-based biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), and others.

Retrophin is currently enrolling patients in a potentially pivotal Phase II clinical trial of its lead compound, sparsentan, for FSGS. The Company intends to advance RE-024 for the treatment of PKAN by filing a U.S. IND in the first half of 2015 to support the initiation of a Phase I study. Retrophin has also filed a provisional patent covering a novel formulation of RE-034 for the potential treatment of several rare diseases.

View all »   RSSRecent Releases

Nov 16, 2015
Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis

Nov 5, 2015
Retrophin Announces Research Collaboration With the Grace Wilsey Foundation and the Warren Family Research Center for Drug Discovery and Development at the University of Notre Dame